Prostate Cancer - Results from #780

Prostate cancer: nuclear medicine imaging in the biochemical recurrence and in oligometastatic disease. June 12, 2024

Race-related Differences in Sipuleucel-T Response Among Men with Metastatic Castrate-Resistant Prostate Cancer. June 12, 2024

New target therapies in prostate cancer: from radioligand therapy, to PARP-inhibitors and immunotherapy. June 12, 2024

Small cell neuroendocrine prostate cancer with adenocarcinoma components-case report and literature review. June 11, 2024

Research protocol for an observational health data analysis to assess the applicability of randomized controlled trials focusing on newly diagnosed metastatic prostate cancer using real-world data: PIONEER IMI's "big data for better outcomes" program. June 11, 2024

Acceptability of a virtual prostate cancer survivorship care model in rural Australia: A multi-methods, single-centre feasibility pilot. June 11, 2024

A phase II trial of apalutamide for intermediate-risk prostate cancer and molecular correlates. June 11, 2024

A qualitative approach to understanding the drivers of unequal receipt of definitive therapy for Black men with prostate cancer in Massachusetts. June 11, 2024

Surgical gestures to evaluate apical dissection of robot-assisted radical prostatectomy. June 10, 2024

International Variations in Adherence to Quality Metrics for Locoregional Prostate Cancer. June 10, 2024

Evaluation of Treatment Outcomes of Prostate Cancer Patients With Lymph Node Metastasis Treated With Definitive Radiotherapy: Comparative Analysis of PSMA PET/CT and Conventional Imaging. June 10, 2024

Prostate Cancer Recurrence: Examining the Role of Salvage Radiotherapy Field and Risk Factors for Regional Disease Recurrence Captured on 18F-DCFPyL PET/CT. June 10, 2024

A Prospective Randomized Multicenter Study on the Impact of [18F]F-Choline PET/CT Versus Conventional Imaging for Staging Intermediate- to High-Risk Prostate Cancer. June 10, 2024

PET radiotracers for whole-body in vivo molecular imaging of prostatic neuroendocrine malignancies. June 10, 2024

Urinary extracellular vesicle-derived miR-126-3p predicts lymph node invasion in patients with high-risk prostate cancer. June 7, 2024

The psychosocial impact of prostate cancer screening for BRCA1 and BRCA2 carriers. June 7, 2024

Receipt of prostate-specific antigen test in Medicaid beneficiaries with and without HIV in 2001-2015 in 14 states. June 7, 2024

Cardiovascular Events and Androgen Receptor Signaling Inhibitors in Advanced Prostate Cancer: A Systematic Review and Meta-Analysis. June 7, 2024

Natural language processing pipeline to extract prostate cancer-related information from clinical notes. June 7, 2024

Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group. June 6, 2024

Page 40 of 1437